Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK

Clay, E., Jamotte, A. orcid.org/0000-0003-2274-4361, Verhamme, P. et al. (3 more authors) (2018) Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy , 6 (1). ISSN 2001-6689

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Edoxaban; Markov model; anticoagulant; cost-effectiveness; deep vein thrombosis; economic evaluation; pulmonary embolism; venous thromboembolism; warfarin
Dates:
  • Published: 17 July 2018
  • Accepted: 27 June 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 07 Sep 2018 10:47
Last Modified: 07 Sep 2018 10:48
Published Version: https://doi.org/10.1080/20016689.2018.1495974
Status: Published online
Publisher: Taylor & Francis
Refereed: Yes
Identification Number: https://doi.org/10.1080/20016689.2018.1495974
Related URLs:

Share / Export

Statistics